Apogee director-linked entity granted 7,657 options

Apogee Therapeutics director Nimish P. Shah reported a grant of stock options covering 7,657 shares of common stock, with an exercise price of 85.00 and expiration on 2036-06-09.

Rhea-AI Filing Summary

Apogee Therapeutics director Nimish P. Shah reported a grant of stock options covering 7,657 shares of common stock, with an exercise price of 85.00 and expiration on 2036-06-09. The options vest on the one-year anniversary of the 2026-06-09 grant date.

Under an agreement, the option and underlying shares are held for the sole benefit of Venrock Management, LLC, which directs any exercise and is entitled to the shares. Shah may be deemed an indirect beneficial owner only to the extent of his pecuniary interest.

Insider Trade Summary

Grant/Award: 7,657 shares

Grant/Award 1 txn

Insider Shah Nimish P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,657	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 7,657 contracts (Direct)

Footnotes (2)

1. F1. This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.
2. F2. Under an agreement between the Reporting Person and Venrock Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

Key Figures

Option grant size: 7,657 options Exercise price: 85.00 per share Expiration date: 2036-06-09 +1 more

4 metrics

Option grant size 7,657 options Stock Option (Right to Buy) granted 2026-06-09

Exercise price 85.00 per share Stock option exercise price for 7,657 underlying shares

Expiration date 2036-06-09 Option term end for the 7,657-share grant

Post-transaction derivative holdings 7,657 options Total derivative securities following the reported grant

Key Terms

Stock Option (Right to Buy), indirect beneficial owner, pecuniary interest

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

indirect beneficial owner financial

"The Management Company may be deemed the indirect beneficial owner of the shares"

pecuniary interest financial

"The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Apogee Therapeutics (APGE) report for Nimish P. Shah?

Apogee Therapeutics reported that director Nimish P. Shah received a grant of stock options for 7,657 shares of common stock. These options were awarded at an exercise price of 85.00 and are scheduled to expire on 2036-06-09, subject to standard vesting conditions.

When do Nimish P. Shah’s Apogee Therapeutics (APGE) options vest and expire?

The granted stock options for 7,657 Apogee Therapeutics shares vest on the one-year anniversary of the 2026-06-09 grant date. They carry an expiration date of 2036-06-09, giving a ten-year term from grant, assuming continued service through the vesting date.

Who is the beneficial owner of the Apogee Therapeutics (APGE) options linked to Nimish P. Shah?

The options and underlying shares are held for the sole benefit of Venrock Management, LLC. Shah must exercise the options only at Venrock’s direction, and Venrock may be deemed the indirect beneficial owner, while Shah disclaims ownership beyond his pecuniary interest.

Does Nimish P. Shah directly benefit from the Apogee Therapeutics (APGE) option grant?

Shah is deemed to hold the options for Venrock Management, LLC and must follow its directions regarding exercise. He may be considered an indirect beneficial owner only to the extent of his pecuniary interest, and he expressly disclaims beneficial ownership beyond that interest.

Is the Apogee Therapeutics (APGE) Form 4 transaction a market purchase or sale?

The Form 4 reflects a grant of stock options, not an open market purchase or sale. It is categorized as an acquisition of a derivative security, with 7,657 options awarded at an exercise price of 85.00, expiring on 2036-06-09, subject to vesting after one year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 08:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shah Nimish P

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$85	06/09/2026		A		7,657		(1)	06/09/2036	Common Stock	7,657	$0.00	7,657	D(2)

Explanation of Responses:

1. This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

2. Under an agreement between the Reporting Person and Venrock Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

	/s/ Matthew Batters, as attorney-in-fact for Nimish Shah	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)